Accumulating evidence suggests that IgA and other immunoglobulins play a significant role in the interplay between cancer development and the immune response, potentially influencing the efficacy of immunotherapies and the body’s ability to combat tumor growth (42, 43). This evidence concerns the gene CD79A and cancer.